Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

88 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Hydrofluoroalkane-134a beclomethasone dipropionate, 400 microg, is as effective as chlorofluorocarbon beclomethasone dipropionate, 800 microg, for the treatment of moderate asthma.
Gross G, Thompson PJ, Chervinsky P, Vanden Burgt J. Gross G, et al. Chest. 1999 Feb;115(2):343-51. doi: 10.1378/chest.115.2.343. Chest. 1999. PMID: 10027430 Clinical Trial.
Effects of montelukast and beclomethasone on airway function and asthma control.
Israel E, Chervinsky PS, Friedman B, Van Bavel J, Skalky CS, Ghannam AF, Bird SR, Edelman JM. Israel E, et al. J Allergy Clin Immunol. 2002 Dec;110(6):847-54. doi: 10.1067/mai.2002.129413. J Allergy Clin Immunol. 2002. PMID: 12464949 Clinical Trial.
Fluticasone Propionate Reduces Oral Prednisone Use While it Improves Asthma Control.
Noonan M, Chervinsky P, Busse WW, Weisberg SC, Pinnas J, De Boisblanc BP, Boltansky H, Pearlman D, Repsher L, Kellerman D. Noonan M, et al. Am J Ther. 1996 Jul;3(7):497-505. doi: 10.1097/00045391-199607000-00005. Am J Ther. 1996. PMID: 11862281
In addition, the number of nighttime awakenings and symptomatic albuterol use declined relative to placebo values (p < 0.05). ...
In addition, the number of nighttime awakenings and symptomatic albuterol use declined relative to placebo values (p < 0.05). ...
Effects of treatment with mometasone furoate dry powder inhaler in children with persistent asthma.
Berger WE, Milgrom H, Chervinsky P, Noonan M, Weinstein SF, Lutsky BN, Staudinger H. Berger WE, et al. Among authors: chervinsky p. Ann Allergy Asthma Immunol. 2006 Nov;97(5):672-80. doi: 10.1016/S1081-1206(10)61099-X. Ann Allergy Asthma Immunol. 2006. PMID: 17165278 Clinical Trial.
Fluticasone propionate HFA-134a pressurized metered-dose inhaler in adolescents and adults with moderate to severe asthma.
Pinnas JL, Noonan MJ, Weinstein SF, Chervinsky P, Scott CA, Herje NE, Wu W, Crim C. Pinnas JL, et al. J Asthma. 2005 Dec;42(10):865-71. doi: 10.1080/02770900500371294. J Asthma. 2005. PMID: 16393726 Clinical Trial.
Mean change from baseline to endpoint in pre-dose percent predicted forced expiratory volume in one second (FEV1) was greater (p < 0.001) in each fluticasone propionate group (9.0%, 88 microg bid; 9.8%, 220 microg bid; 11.2%, 440 microg bid) versus placebo (3.4%). ...
Mean change from baseline to endpoint in pre-dose percent predicted forced expiratory volume in one second (FEV1) was greater (p < …
Efficacy and safety of doxofylline compared to theophylline in chronic reversible asthma -- a double-blind randomized placebo-controlled multicentre clinical trial.
Goldstein MF, Chervinsky P. Goldstein MF, et al. Med Sci Monit. 2002 Apr;8(4):CR297-304. Med Sci Monit. 2002. PMID: 11951074 Clinical Trial.
(p=0.001). With doxofylline 400 mg t.i.d., the number of patients treated to spare one drop-out due to theophylline was 5. CONCLUSIONS: This study provides evidence that doxofylline 400 mg t.i.d. is an effective treatment for relieving airway obstruction and displays a bet …
(p=0.001). With doxofylline 400 mg t.i.d., the number of patients treated to spare one drop-out due to theophylline was 5. CONCLUSION …
A comparison of the effects of oral montelukast and inhaled salmeterol on response to rescue bronchodilation after challenge.
Storms W, Chervinsky P, Ghannam AF, Bird S, Hustad CM, Edelman JM; Challenge-Rescue Study Group. Storms W, et al. Respir Med. 2004 Nov;98(11):1051-62. doi: 10.1016/j.rmed.2004.05.008. Respir Med. 2004. PMID: 15526805 Clinical Trial.

RESULTS: Maximum achievable forced expiratory volume in 1 s (FEV1) percent predicted after rescue beta2-agonist improved in the montelukast (+1.5%) and placebo (+1.2%) groups at 4 weeks, but diminished in the salmeterol (-3.9%) group (P < 0.001). Although pre-exercise F

RESULTS: Maximum achievable forced expiratory volume in 1 s (FEV1) percent predicted after rescue beta2-agonist improved in the montelukast …
Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate.
Skoner DP, Rachelefsky GS, Meltzer EO, Chervinsky P, Morris RM, Seltzer JM, Storms WW, Wood RA. Skoner DP, et al. Pediatrics. 2000 Feb;105(2):E23. doi: 10.1542/peds.105.2.e23. Pediatrics. 2000. PMID: 10654983 Clinical Trial.
Comparison of mometasone furoate administered by metered dose inhaler with beclomethasone dipropionate.
Chervinsky P, Nelson HS, Bernstein DI, Berkowitz RA, Siegel SC. Chervinsky P, et al. Int J Clin Pract. 2002 Jul-Aug;56(6):419-25. Int J Clin Pract. 2002. PMID: 12166539 Clinical Trial.
At endpoint, FEV1 was significantly improved (p<0.01) with MF-MDI 56, 200 and 500 microg b.i.d., as well as with BDP (6%, 13%, 14% and 4%, respectively), compared with placebo (-12%). Mean change in FVC, FEF2575%, and a.m. and p.m. peak expiratory flow rate (PEFR …
At endpoint, FEV1 was significantly improved (p<0.01) with MF-MDI 56, 200 and 500 microg b.i.d., as well as with BDP (6%, 13%, 14% …
Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group.
Reiss TF, Chervinsky P, Dockhorn RJ, Shingo S, Seidenberg B, Edwards TB. Reiss TF, et al. Arch Intern Med. 1998 Jun 8;158(11):1213-20. doi: 10.1001/archinte.158.11.1213. Arch Intern Med. 1998. PMID: 9625400 Clinical Trial.
RESULTS: Montelukast improved airway obstruction (forced expiratory volume in 1 second, morning and evening peak expiratory flow rate) and patient-reported end points (daytime asthma symptoms, "as-needed" beta-agonist use, nocturnal awakenings) (P<.001 compared with pla …
RESULTS: Montelukast improved airway obstruction (forced expiratory volume in 1 second, morning and evening peak expiratory flow rate) and p …
88 results
Jump to page
Feedback